Dyax Corp (DYAX) Reports In-Line Q1 EPS

Dyax Corp (NASDAQ: DYAX) reported Q1 EPS of ($0.05), in-line with the analyst estimate of ($0.05). Revenue for the quarter came in at $20.4 million versus the consensus estimate of $21.79 million.

Financial Guidance

• Dyax has re-iterated its financial guidance for 2015.
• Revenue guidance includes two components:
• KALBITOR net sales in the range of $60-70 million, reflecting the Company's expectation that quarterly and annual KALBITOR net sales will fluctuate due to continued volatility in the level of KALBITOR utilization for individual patients. This volatility in utilization rates is due to fluctuations in the number of HAE attacks experienced by patients and the consistency with which patients treat their HAE attacks with KALBITOR.
• Development and license fees in the range of $7-9 million. These fees exclude all potential royalties which would be earned from licensees' sales of LFRP product.

Operating costs and expenses (cost of product sales, research and development expenses, and selling, general and administrative costs) to be in the range of $105-110 million.

For earnings history and earnings-related data on Dyax Corp (DYAX) click here.

You May Also Be Interested In

• Tesla to launch Cybercab in Austin this month - report
• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• Fabrinet (FN) Tops Q4 EPS by 29c, Beats on Revenue; Offers Guidance